Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Repligen Cp (RGEN)

Repligen Cp (RGEN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Repligen Cp 41 SEYON STREET BUILDING 1 SUITE 100 WALTHAM MA 02453 USA

P: 781-250-0111 F: 781-250-0115

Description:

Repligen Corporation is a life sciences company focused on the development, production and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Their bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. They are a leading manufacturer of Protein A, a critical reagent used to separate and purify monoclonal antibody therapeutics. They also supply several growth factor products used to increase cell culture productivity during the fermentation stage of drug manufacturing. In addition, they have developed and marketed their OPUS' series of pre-packed `plug-and-play` chromatography columns, and they provide test kits to ensure final product quality. Aside from their core bioprocessing business, they have a portfolio of clinical-stage partnering assets, including a pancreatic imaging agent in Phase 3 development and an orphan drug candidate in Phase 1 development.

Key Statistics

Overview:

Market Capitalization, $K 7,558,331
Shares Outstanding, K 52,503
Annual Sales, $ 270,250 K
Annual Net Income, $ 21,410 K
Last Quarter Sales, $ 87,460 K
Last Quarter Net Income, $ 15,860 K
60-Month Beta 1.12
% of Insider Shareholders 1.70%
% of Institutional Shareholders 97.87%
Float, K 51,610
% Float 98.30%

Growth:

1-Year Return 75.58%
3-Year Return 271.56%
5-Year Return 423.46%
5-Year Revenue Growth 325.26%
5-Year Earnings Growth 328.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.42 on 07/30/20
Next Earnings Date 10/29/20
Earnings Per Share ttm 1.20
EPS Growth vs. Prev Qtr 31.25%
EPS Growth vs. Prev Year 35.48%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00

RGEN Ratios

Ratio
Price/Earnings ttm 118.21
Price/Earnings forward 78.80
Price/Earnings to Growth 3.96
Return-on-Equity % 5.93%
Return-on-Assets % 4.51%
Profit Margin % 7.92
Net Margin % -4.13
Debt/Equity 0.22
Price/Sales 27.56
Price/Cash Flow 100.62
Price/Book 6.77
Book Value/Share 20.95
Interest Coverage 3.81
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar